Treatment Options for Gout.

BACKGROUND 1-2% of adults in Germany suffer from gout. Gout is one of the few rheumatological diseases that can be cured. It arises through the deposition of uric acid crystals in joints as a result of hyperuricemia. Painful redness and swelling of the affected joints are typical findings. Multiple pertinent guidelines and treatment recommendations have been published, but there is reason to believe that patients with gout are not always treated accordingly. METHODS This review is based on relevant publications from the years 2000-2016 that were retrieved by a selective search in the Cochrane and PubMed databases. RESULTS In a person with normal renal function, asymptomatic hyperuricemia is not an indication for treatment to lower the serum uric acid level. The drugs of first choice for acute gouty arthritis are nonsteroidal antiinflammatory drugs (NSAID), corticosteroids, and colchicine. Treatment with xanthine oxidase inhibitors (XOI) or uricosuric drugs is indicated for patients with a recurrent or severe course; the target uric acid value is <6 mg/dL. Long-term treatment should be initiated only after resolution of the acute attack. For patients with refractory gout, lesinurad (approved in February 2016) in combination with XOI is a new treatment option that can be considered. Comprehensive patient education and counseling is an important component of the treatment of patients with gout. Regular laboratory follow-up is necessary as well. CONCLUSION The prevalence of gout is rising around the world. Patients with gout could benefit greatly from consistent implementation of the existing treatment guidelines and recommendations. In the future, controlled trials should be conducted to determine the best time to start treatment and the optimal target level for the serum uric acid concentration in terms of a risk/benefit analysis.

[1]  K. Saag,et al.  Lesinurad Combined With Allopurinol: A Randomized, Double‐Blind, Placebo‐Controlled Study in Gout Patients With an Inadequate Response to Standard‐of‐Care Allopurinol (a US‐Based Study) , 2017, Arthritis & rheumatology.

[2]  U. Müller-Ladner,et al.  [Full version of the S2e guidelines on gouty arthritis : Evidence-based guidelines of the German Society of Rheumatology (DGRh)]. , 2016, Zeitschrift fur Rheumatologie.

[3]  R. Day,et al.  Allopurinol hypersensitivity: investigating the cause and minimizing the risk , 2016, Nature Reviews Rheumatology.

[4]  N. Parathithasan,et al.  Gouty arthropathy: Review of clinico‐pathologic and imaging features , 2016, Journal of medical imaging and radiation oncology.

[5]  M. Doherty,et al.  Global epidemiology of gout: prevalence, incidence and risk factors , 2015, Nature Reviews Rheumatology.

[6]  A. Ogdie,et al.  2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative , 2015, Annals of the rheumatic diseases.

[7]  A. Ogdie,et al.  2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative , 2015, Annals of the rheumatic diseases.

[8]  F. Perez-Ruiz,et al.  Study for Updated Gout Classification Criteria: Identification of Features to Classify Gout , 2015, Arthritis care & research.

[9]  P. Khanna,et al.  The impact of gout guidelines , 2015, Current opinion in rheumatology.

[10]  J. Frampton.  Febuxostat: A Review of Its Use in the Treatment of Hyperuricaemia in Patients with Gout , 2015, Drugs.

[11]  R. Fleischmann,et al.  Pharmacodynamic, pharmacokinetic and tolerability evaluation of concomitant administration of lesinurad and febuxostat in gout patients with hyperuricaemia. , 2014, Rheumatology.

[12]  C. van Durme,et al.  Non-steroidal anti-inflammatory drugs for acute gout. , 2014, The Cochrane database of systematic reviews.

[13]  R. Buchbinder,et al.  Interleukin-1 inhibitors for acute gout. , 2014, The Cochrane database of systematic reviews.

[14]  C. Bombardier,et al.  Treatment of asymptomatic hyperuricemia for the prevention of gouty arthritis, renal disease, and cardiovascular events: a systematic literature review. , 2014, The Journal of rheumatology. Supplement.

[15]  F. Becce,et al.  2016 updated EULAR evidence-based recommendations for the management of gout , 2014, Annals of the rheumatic diseases.

[16]  E. Roddy,et al.  Improvement in the management of gout is vital and overdue: an audit from a UK primary care medical practice , 2013, BMC Family Practice.

[17]  R. Buchbinder,et al.  Lifestyle interventions for acute gout. , 2013, The Cochrane database of systematic reviews.

[18]  T. Kiernan,et al.  Independent and conjoint associations of gout and hyperuricaemia with total and cardiovascular mortality. , 2013, QJM : monthly journal of the Association of Physicians.

[19]  R. Buchbinder,et al.  Lifestyle interventions for chronic gout. , 2013, The Cochrane database of systematic reviews.

[20]  R. Buchbinder,et al.  Intra-articular glucocorticoids for acute gout. , 2013, The Cochrane database of systematic reviews.

[21]  N. Dalbeth,et al.  Imaging of gout: an overview. , 2012, Best practice & research. Clinical rheumatology.

[22]  M. Suarez‐Almazor,et al.  Febuxostat for treating chronic gout. , 2012, The Cochrane database of systematic reviews.

[23]  T. Taylor,et al.  Initiation of allopurinol at first medical contact for acute attacks of gout: a randomized clinical trial. , 2012, The American journal of medicine.

[24]  Charles King,et al.  2012 American College of Rheumatology guidelines for management of gout. Part 1: Systematic nonpharmacologic and pharmacologic therapeutic approaches to hyperuricemia , 2012, Arthritis care & research.

[25]  R. Terkeltaub,et al.  2012 American College of Rheumatology guidelines for management of gout. Part 2: Therapy and antiinflammatory prophylaxis of acute gouty arthritis , 2012, Arthritis care & research.

[26]  M. Doherty,et al.  Patients with gout adhere to curative treatment if informed appropriately: proof-of-concept observational study , 2012, Annals of the rheumatic diseases.

[27]  R. Jordan,et al.  The Management of Gout in Primary Care , 2012 .

[28]  A. So,et al.  Ätiologie und Management der Gicht , 2012, Zeitschrift für Rheumatologie.

[29]  R. Wortmann,et al.  Effect of prophylaxis on gout flares after the initiation of urate-lowering therapy: analysis of data from three phase III trials. , 2010, Clinical therapeutics.

[30]  M. Goicoechea,et al.  Effect of allopurinol in chronic kidney disease progression and cardiovascular risk. , 2010, Clinical journal of the American Society of Nephrology : CJASN.

[31]  C. van Weel,et al.  A diagnostic rule for acute gouty arthritis in primary care without joint fluid analysis. , 2010, Archives of internal medicine.

[32]  E. Krishnan.  Inflammation, oxidative stress and lipids: the risk triad for atherosclerosis in gout. , 2010, Rheumatology.

[33]  R. Terkeltaub,et al.  High versus low dosing of oral colchicine for early acute gout flare: Twenty-four-hour outcome of the first multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-comparison colchicine study. , 2010, Arthritis and rheumatism.

[34]  Hyon K. Choi.  A prescription for lifestyle change in patients with hyperuricemia and gout , 2010, Current opinion in rheumatology.

[35]  M. Reuss-Borst.  Differentialdiagnostik und Therapie der Gicht , 2009, Medizinische Klinik.

[36]  S. Bornstein,et al.  Gout--current diagnosis and treatment. , 2009, Deutsches Arzteblatt international.

[37]  H. Schumacher,et al.  Effects of febuxostat versus allopurinol and placebo in reducing serum urate in subjects with hyperuricemia and gout: a 28-week, phase III, randomized, double-blind, parallel-group trial. , 2008, Arthritis and rheumatism.

[38]  J. Hodges,et al.  Opportunities for improving medication use and monitoring in gout , 2008, Annals of the rheumatic diseases.

[39]  M. A. van de Laar,et al.  A randomised controlled trial on the efficacy and tolerability with dose escalation of allopurinol 300–600 mg/day versus benzbromarone 100–200 mg/day in patients with gout , 2008, Annals of the rheumatic diseases.

[40]  C. Weel,et al.  Use of oral prednisolone or naproxen for the treatment of gout arthritis: a double-blind, randomised equivalence trial , 2008, The Lancet.

[41]  Hyon K. Choi,et al.  Soft drinks, fructose consumption, and the risk of gout in men: prospective cohort study , 2008, BMJ : British Medical Journal.

[42]  L. Annemans,et al.  Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000–2005 , 2007, Annals of the rheumatic diseases.

[43]  M. Doherty,et al.  The changing epidemiology of gout , 2007, Nature Clinical Practice Rheumatology.

[44]  M. Doherty,et al.  Concordance of the management of chronic gout in a UK primary-care population with the EULAR gout recommendations , 2007, Annals of the rheumatic diseases.

[45]  J. Nolla,et al.  Using serum urate levels to determine the period free of gouty symptoms after withdrawal of long-term urate-lowering therapy: a prospective study. , 2006, Arthritis and rheumatism.

[46]  N. Schlesinger,et al.  Allopurinol for chronic gout , 2006 .

[47]  P Netter,et al.  EULAR evidence based recommendations for gout. Part II: Management. Report of a task force of the EULAR Standing Committee For International Clinical Studies Including Therapeutics (ESCISIT) , 2006, Annals of the rheumatic diseases.

[48]  P Netter,et al.  EULAR evidence based recommendations for gout. Part I: Diagnosis. Report of a task force of the standing committee for international clinical studies including therapeutics (ESCISIT) , 2006, Annals of the rheumatic diseases.

[49]  H. Schumacher,et al.  Febuxostat compared with allopurinol in patients with hyperuricemia and gout. , 2005, The New England journal of medicine.

[50]  Hyon K. Choi,et al.  Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. , 2005, Archives of internal medicine.

[51]  Paul A. Roberts,et al.  Mechanisms of benzarone and benzbromarone‐induced hepatic toxicity , 2005 .

[52]  M. Abel,et al.  Colchicine for prophylaxis of acute flares when initiating allopurinol for chronic gouty arthritis. , 2004, The Journal of rheumatology.

[53]  R. Terkeltaub.  Clinical practice. Gout. , 2003, The New England journal of medicine.

[54]  D. Levinson,et al.  Asymptomatic hyperuricemia: to treat or not to treat. , 2002, Cleveland Clinic journal of medicine.

[55]  R. Glynn,et al.  Asymptomatic hyperuricemia. Risks and consequences in the Normative Aging Study. , 1987, The American journal of medicine.

[56]  B. Ames,et al.  Uric acid provides an antioxidant defense in humans against oxidant- and radical-caused aging and cancer: a hypothesis. , 1981, Proceedings of the National Academy of Sciences of the United States of America.

[57]  S. Krähenbühl,et al.  Mechanisms of benzarone and benzbromarone-induced hepatic toxicity. , 2005, Hepatology.